Global Cancer Vaccines Market - 2025 -2033
Global Cancer Vaccines Market: Industry Outlook
The global cancer vaccines market reached US$ 8.82 Billion in 2023, with a rise of US$ 9.27 Billion in 2024 and is expected to reach US$ 14.96 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033.
The global cancer vaccines market is experiencing significant growth due to rising cancer prevalence, immunotherapy advancements, and personalized medicine adoption. Cancer vaccines, both preventive and therapeutic, are gaining traction as innovative tools in oncology. The COVID-19 pandemic has accelerated research and investment in cancer vaccine technologies. Government initiatives, R&D pipelines, and strategic collaborations between biotech firms and pharmaceutical giants are contributing to market expansion.
However, challenges such as high development costs, regulatory frameworks, and complex cancer biology limit vaccine efficacy. Emerging opportunities like AI-driven vaccine design, neoantigen-based personalized vaccines, and growing demand in emerging economies present promising avenues for future growth. The cancer vaccines market is poised for significant evolution in cancer prevention and treatment.
Global Cancer Vaccines Market Dynamics: Drivers & Restraints
Driver: Rising prevalence of cancer worldwide
The global cancer prevalence is driving the growth of the cancer vaccines market. As a leading cause of mortality, there is a need for more effective, targeted, and less invasive treatment options. Research and development efforts are intensifying towards preventive and therapeutic vaccines that can either stop cancer before it starts or support the immune system in fighting existing tumors.
Healthcare systems and pharmaceutical companies prioritize vaccine-based solutions for long-term immunity and fewer side effects compared to conventional therapies. As awareness among patients and healthcare professionals increases, the demand for innovative cancer vaccines is increasing, making the escalating cancer prevalence a key catalyst for market expansion.
For instance, in 2050, the global cancer burden is expected to rise by 77%, reaching 35 million new cases, largely due to population ageing, population growth, and changes in exposure to risk factors. Key factors include tobacco, alcohol, obesity, and air pollution. High-Income Countries (HICD) are expected to experience the greatest increase in cancer cases, with an additional 4.8 million predicted. However, the proportional increase is most significant in low and medium-HDI countries, with cancer mortality projected to almost double in these regions.
Driver: Advancements in immunotherapy and mRNA vaccine technology
Advancements in immunotherapy and mRNA vaccine technology have significantly shaped the global cancer vaccines market, transforming its trajectory and future potential. Immunotherapy enhances the body's immune response to detect and destroy cancer cells, leading to successful treatments like immune checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies.
Cancer vaccines, particularly therapeutic ones, use tumor-associated or neoantigens to prime the immune system to recognize and attack cancer cells with precision. mRNA vaccine platforms, demonstrated during the COVID-19 pandemic, offer unprecedented speed in development, scalability in manufacturing, and flexibility in design. These advantages have catalyzed the exploration of mRNA technology for cancer vaccines, particularly in creating personalized or tumor-specific vaccines tailored to individual patient profiles.
Companies like Moderna, BioNTech, and CureVac are heavily investing in cancer vaccine pipelines using mRNA platforms that encode tumor antigens and stimulate targeted immune responses. These advancements are enhancing the efficacy and safety of cancer vaccines, reducing barriers to innovation, and establishing cancer vaccines as a vital component of next-generation oncology care.
Restraint: Stringent regulatory approval processes
The global cancer vaccine market faces significant challenges due to stringent regulatory approval processes. These processes require extensive preclinical data and multi-phase clinical trials, which can take years and require substantial financial investment. Cancer is a complex and heterogeneous disease, making it difficult to establish standardized endpoints and biomarkers across patient populations. The lack of historical precedent for personalized or novel vaccine platforms like mRNA or viral vectors can increase scrutiny and uncertainty in approval timelines. These regulatory hurdles not only increase development costs but also pose barriers for smaller biotech companies with limited resources, affecting the pace of innovative cancer vaccines reaching patients in need.
Opportunity: Growth in point-of-care and portable testing solutions
Personalized cancer vaccines, designed using neoantigens, are a promising shift towards precision medicine in the global market. These vaccines target cancer cells with high specificity, sparing healthy tissue, enhancing the potential for robust immune responses, especially in resistant cancers. Tailoring vaccines to each patient's tumor profile improves treatment outcomes and minimizes adverse effects, making them ideal candidates for combination therapies with checkpoint inhibitors or chemotherapy. Advancements in technologies like mRNA and AI-driven antigen discovery are moving closer to commercial viability, with several candidates in clinical trials for melanoma, lung, and gastrointestinal cancers. This growing field presents opportunities for biotech innovation, strategic partnerships, and long-term market growth.
Global Cancer Vaccines Market Segment Analysis
The global cancer vaccines market is segmented based on type, cancer type, technology, route of administration, end user, and region.
Type:
The preventive cancer vaccines of this type are expected to have 51.33% of the cancer vaccines market share.
The preventive cancer vaccines segment is a significant driver in the global cancer vaccines market due to the growing focus on early disease prevention, vaccine efficacy awareness, and government initiatives. HPV and Hepatitis B vaccines have proven effective in preventing cancers caused by viral infections, encouraging mass immunization programs worldwide.
For instance, in January 2025, GSK invested ?50 million in a collaboration with Oxford to advance cancer research, potentially influencing future vaccine development. The GSK-Oxford Cancer Immuno-Prevention Programme aims to explore the potential of cancer prevention through vaccination.
The widespread adoption of HPV vaccines, particularly among adolescent populations, has contributed to the market's growth. Government policies, improved cold chain logistics, and healthcare infrastructure, particularly in emerging economies, have bolstered vaccine uptake. Technological innovations, increased R&D funding, and global collaborations between public and private entities are streamlining the development and regulatory approval of newer preventive vaccines targeting different virus-related cancers.
As the burden of preventable cancers continues to rise, the demand for cost-effective and scalable preventive solutions is expected to accelerate, cementing the pivotal role of this segment in driving the global cancer vaccines market's growth.
Global Cancer Vaccines Market - Geographical Analysis
The North America global cancer vaccines market was valued at 3.90 Bllion in 2024
North America dominates the global cancer vaccines market due to advanced healthcare infrastructure, high public and private investment in oncology research, and early adoption of immunization technologies. Major pharmaceutical and biotechnology companies are actively involved in vaccine development, clinical trials, and regulatory submissions.
Government support, fast-track FDA approvals, and funding for cancer prevention initiatives accelerate market growth. High awareness about cancer prevention, routine screening programs, and access to preventive healthcare led to strong uptake of HPV and Hepatitis B vaccines. The rising prevalence of lifestyle-related cancers and a well-established reimbursement framework enhance market penetration and patient compliance. For instance, in August 2024, UCLA Health launched a clinical trial using a personalized cancer vaccine to combat aggressive brain tumors in adolescents and young adults.
The Asia-Pacific global cancer vaccines market was valued at 2.17 Billion in 2024
The Asia-Pacific region is experiencing a significant growth in the market for cancer vaccines due to factors such as an aging population, rising cancer incidence, and increased public awareness. Countries like China, India, Japan, and South Korea are investing in national immunization programs and healthcare reforms to improve access to preventive healthcare solutions, including cancer vaccines.
Moreover, economic growth and expanding healthcare infrastructure are making advanced cancer care more accessible. The region's surge in local vaccine manufacturing capabilities and collaborations between domestic and global pharmaceutical players are also contributing to cost reduction and improved vaccine availability.
For instance, in July 2024, Anixa Biosciences received a 'Decision to Grant' notice from the Japan Patent Office for its 'Vaccine Adjuvants and Formulations' patent application, extending claims for a novel breast cancer vaccine technology beyond the U.S. and European patents previously awarded, according to Anixa Chairman and CEO Dr. Amit Kumar.
Global Cancer Vaccines Market – Major Players
The major players in the cancer vaccines market include Merck & Co., Inc., GlaxoSmithKline plc (GSK), and Dendreon Pharmaceuticals LLC, among others.
Global Cancer Vaccines Market – Emerging Players
The emerging players in the cancer vaccines market include Candel Therapeutics, Elicio Therapeutics, Evaxion, Imugene, Nouscom, OSE Immunotherapeutics, Scancell, and Takis, among others.
Global Cancer Vaccines Market – Key Developments
The global cancer vaccines market is experiencing significant growth, reaching US$ 9.27 Billion in 2024 and projected to reach US$ 14.96 Billion by 2033 at a CAGR of 5.5%.
This growth is driven by the increasing global cancer burden, immunotherapy preference, and advancements in mRNA technologies and personalized vaccines. Preventive vaccines, particularly for HPV and Hepatitis B, remain dominant with a 61.6% market share.
North America leads the market due to its mature healthcare infrastructure and FDA support, while Asia-Pacific is emerging due to rising incidence rates and healthcare investments. Opportunities in AI-driven neoantigen discovery, point-of-care innovation, and biotech collaborations signal a transformative phase for cancer prevention and treatment. Key players like Merck, GSK, and Dendreon are driving this evolution.
The global cancer vaccines market report delivers a detailed analysis with 57 key tables, more than 71 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
The global cancer vaccines market reached US$ 8.82 Billion in 2023, with a rise of US$ 9.27 Billion in 2024 and is expected to reach US$ 14.96 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033.
The global cancer vaccines market is experiencing significant growth due to rising cancer prevalence, immunotherapy advancements, and personalized medicine adoption. Cancer vaccines, both preventive and therapeutic, are gaining traction as innovative tools in oncology. The COVID-19 pandemic has accelerated research and investment in cancer vaccine technologies. Government initiatives, R&D pipelines, and strategic collaborations between biotech firms and pharmaceutical giants are contributing to market expansion.
However, challenges such as high development costs, regulatory frameworks, and complex cancer biology limit vaccine efficacy. Emerging opportunities like AI-driven vaccine design, neoantigen-based personalized vaccines, and growing demand in emerging economies present promising avenues for future growth. The cancer vaccines market is poised for significant evolution in cancer prevention and treatment.
Global Cancer Vaccines Market Dynamics: Drivers & Restraints
Driver: Rising prevalence of cancer worldwide
The global cancer prevalence is driving the growth of the cancer vaccines market. As a leading cause of mortality, there is a need for more effective, targeted, and less invasive treatment options. Research and development efforts are intensifying towards preventive and therapeutic vaccines that can either stop cancer before it starts or support the immune system in fighting existing tumors.
Healthcare systems and pharmaceutical companies prioritize vaccine-based solutions for long-term immunity and fewer side effects compared to conventional therapies. As awareness among patients and healthcare professionals increases, the demand for innovative cancer vaccines is increasing, making the escalating cancer prevalence a key catalyst for market expansion.
For instance, in 2050, the global cancer burden is expected to rise by 77%, reaching 35 million new cases, largely due to population ageing, population growth, and changes in exposure to risk factors. Key factors include tobacco, alcohol, obesity, and air pollution. High-Income Countries (HICD) are expected to experience the greatest increase in cancer cases, with an additional 4.8 million predicted. However, the proportional increase is most significant in low and medium-HDI countries, with cancer mortality projected to almost double in these regions.
Driver: Advancements in immunotherapy and mRNA vaccine technology
Advancements in immunotherapy and mRNA vaccine technology have significantly shaped the global cancer vaccines market, transforming its trajectory and future potential. Immunotherapy enhances the body's immune response to detect and destroy cancer cells, leading to successful treatments like immune checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies.
Cancer vaccines, particularly therapeutic ones, use tumor-associated or neoantigens to prime the immune system to recognize and attack cancer cells with precision. mRNA vaccine platforms, demonstrated during the COVID-19 pandemic, offer unprecedented speed in development, scalability in manufacturing, and flexibility in design. These advantages have catalyzed the exploration of mRNA technology for cancer vaccines, particularly in creating personalized or tumor-specific vaccines tailored to individual patient profiles.
Companies like Moderna, BioNTech, and CureVac are heavily investing in cancer vaccine pipelines using mRNA platforms that encode tumor antigens and stimulate targeted immune responses. These advancements are enhancing the efficacy and safety of cancer vaccines, reducing barriers to innovation, and establishing cancer vaccines as a vital component of next-generation oncology care.
Restraint: Stringent regulatory approval processes
The global cancer vaccine market faces significant challenges due to stringent regulatory approval processes. These processes require extensive preclinical data and multi-phase clinical trials, which can take years and require substantial financial investment. Cancer is a complex and heterogeneous disease, making it difficult to establish standardized endpoints and biomarkers across patient populations. The lack of historical precedent for personalized or novel vaccine platforms like mRNA or viral vectors can increase scrutiny and uncertainty in approval timelines. These regulatory hurdles not only increase development costs but also pose barriers for smaller biotech companies with limited resources, affecting the pace of innovative cancer vaccines reaching patients in need.
Opportunity: Growth in point-of-care and portable testing solutions
Personalized cancer vaccines, designed using neoantigens, are a promising shift towards precision medicine in the global market. These vaccines target cancer cells with high specificity, sparing healthy tissue, enhancing the potential for robust immune responses, especially in resistant cancers. Tailoring vaccines to each patient's tumor profile improves treatment outcomes and minimizes adverse effects, making them ideal candidates for combination therapies with checkpoint inhibitors or chemotherapy. Advancements in technologies like mRNA and AI-driven antigen discovery are moving closer to commercial viability, with several candidates in clinical trials for melanoma, lung, and gastrointestinal cancers. This growing field presents opportunities for biotech innovation, strategic partnerships, and long-term market growth.
Global Cancer Vaccines Market Segment Analysis
The global cancer vaccines market is segmented based on type, cancer type, technology, route of administration, end user, and region.
Type:
The preventive cancer vaccines of this type are expected to have 51.33% of the cancer vaccines market share.
The preventive cancer vaccines segment is a significant driver in the global cancer vaccines market due to the growing focus on early disease prevention, vaccine efficacy awareness, and government initiatives. HPV and Hepatitis B vaccines have proven effective in preventing cancers caused by viral infections, encouraging mass immunization programs worldwide.
For instance, in January 2025, GSK invested ?50 million in a collaboration with Oxford to advance cancer research, potentially influencing future vaccine development. The GSK-Oxford Cancer Immuno-Prevention Programme aims to explore the potential of cancer prevention through vaccination.
The widespread adoption of HPV vaccines, particularly among adolescent populations, has contributed to the market's growth. Government policies, improved cold chain logistics, and healthcare infrastructure, particularly in emerging economies, have bolstered vaccine uptake. Technological innovations, increased R&D funding, and global collaborations between public and private entities are streamlining the development and regulatory approval of newer preventive vaccines targeting different virus-related cancers.
As the burden of preventable cancers continues to rise, the demand for cost-effective and scalable preventive solutions is expected to accelerate, cementing the pivotal role of this segment in driving the global cancer vaccines market's growth.
Global Cancer Vaccines Market - Geographical Analysis
The North America global cancer vaccines market was valued at 3.90 Bllion in 2024
North America dominates the global cancer vaccines market due to advanced healthcare infrastructure, high public and private investment in oncology research, and early adoption of immunization technologies. Major pharmaceutical and biotechnology companies are actively involved in vaccine development, clinical trials, and regulatory submissions.
Government support, fast-track FDA approvals, and funding for cancer prevention initiatives accelerate market growth. High awareness about cancer prevention, routine screening programs, and access to preventive healthcare led to strong uptake of HPV and Hepatitis B vaccines. The rising prevalence of lifestyle-related cancers and a well-established reimbursement framework enhance market penetration and patient compliance. For instance, in August 2024, UCLA Health launched a clinical trial using a personalized cancer vaccine to combat aggressive brain tumors in adolescents and young adults.
The Asia-Pacific global cancer vaccines market was valued at 2.17 Billion in 2024
The Asia-Pacific region is experiencing a significant growth in the market for cancer vaccines due to factors such as an aging population, rising cancer incidence, and increased public awareness. Countries like China, India, Japan, and South Korea are investing in national immunization programs and healthcare reforms to improve access to preventive healthcare solutions, including cancer vaccines.
Moreover, economic growth and expanding healthcare infrastructure are making advanced cancer care more accessible. The region's surge in local vaccine manufacturing capabilities and collaborations between domestic and global pharmaceutical players are also contributing to cost reduction and improved vaccine availability.
For instance, in July 2024, Anixa Biosciences received a 'Decision to Grant' notice from the Japan Patent Office for its 'Vaccine Adjuvants and Formulations' patent application, extending claims for a novel breast cancer vaccine technology beyond the U.S. and European patents previously awarded, according to Anixa Chairman and CEO Dr. Amit Kumar.
Global Cancer Vaccines Market – Major Players
The major players in the cancer vaccines market include Merck & Co., Inc., GlaxoSmithKline plc (GSK), and Dendreon Pharmaceuticals LLC, among others.
Global Cancer Vaccines Market – Emerging Players
The emerging players in the cancer vaccines market include Candel Therapeutics, Elicio Therapeutics, Evaxion, Imugene, Nouscom, OSE Immunotherapeutics, Scancell, and Takis, among others.
Global Cancer Vaccines Market – Key Developments
- In March 2025, Everest Medicines administered its personalised mRNA cancer vaccine, EVM16, to the first subject in a first-in-human trial, EVM16CX01. The trial, conducted at Peking University Cancer Hospital in China, aims to assess the vaccine's immunogenicity, safety, preliminary efficacy, and tolerability in individuals with advanced or recurrent solid tumors.
The global cancer vaccines market is experiencing significant growth, reaching US$ 9.27 Billion in 2024 and projected to reach US$ 14.96 Billion by 2033 at a CAGR of 5.5%.
This growth is driven by the increasing global cancer burden, immunotherapy preference, and advancements in mRNA technologies and personalized vaccines. Preventive vaccines, particularly for HPV and Hepatitis B, remain dominant with a 61.6% market share.
North America leads the market due to its mature healthcare infrastructure and FDA support, while Asia-Pacific is emerging due to rising incidence rates and healthcare investments. Opportunities in AI-driven neoantigen discovery, point-of-care innovation, and biotech collaborations signal a transformative phase for cancer prevention and treatment. Key players like Merck, GSK, and Dendreon are driving this evolution.
The global cancer vaccines market report delivers a detailed analysis with 57 key tables, more than 71 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.2. Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.
4.2. Restraints:
4.2.1. The high cost of developing cancer vaccines is expected to hamper the market growth.
4.3. Opportunity
4.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Supply Chain Analysis
5.2. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type Segment
7.2. Preventive Cancer Vaccines*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Therapeutic Cancer Vaccine
8. BY TECHNOLOGY
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology Segment
8.2. Dendritic Cells (DC) Cancer Vaccines*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Recombinant Cancer Vaccines
8.4. Antigen/Adjuvant Cancer Vaccines
8.5. Whole Cell Cancer Vaccines
8.6. Viral Vector & DNA Cancer Vaccines
9. BY CANCER TYPE
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type Segment
9.2. Prostate Cancer*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Cervical Cancer
9.4. Lung Cancer
9.5. Bladder Cancer
9.6. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. COMPANY PROFILES
12.1. ose-immuno*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Merck & Co. Inc.
12.3. IO Biotech
12.4. Medigene AG
12.5. Northwest Biotherapeutics
12.6. GlaxoSmithKline
12.7. Dendreon Pharmaceuticals LLC.
12.8. Dynavax Technologies Corporation
12.9. Immunophotonics
12.10. Codagenix(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.2. Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.
4.2. Restraints:
4.2.1. The high cost of developing cancer vaccines is expected to hamper the market growth.
4.3. Opportunity
4.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Supply Chain Analysis
5.2. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type Segment
7.2. Preventive Cancer Vaccines*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Therapeutic Cancer Vaccine
8. BY TECHNOLOGY
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology Segment
8.2. Dendritic Cells (DC) Cancer Vaccines*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Recombinant Cancer Vaccines
8.4. Antigen/Adjuvant Cancer Vaccines
8.5. Whole Cell Cancer Vaccines
8.6. Viral Vector & DNA Cancer Vaccines
9. BY CANCER TYPE
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type Segment
9.2. Prostate Cancer*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Cervical Cancer
9.4. Lung Cancer
9.5. Bladder Cancer
9.6. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. COMPANY PROFILES
12.1. ose-immuno*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Merck & Co. Inc.
12.3. IO Biotech
12.4. Medigene AG
12.5. Northwest Biotherapeutics
12.6. GlaxoSmithKline
12.7. Dendreon Pharmaceuticals LLC.
12.8. Dynavax Technologies Corporation
12.9. Immunophotonics
12.10. Codagenix(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us
LIST OF TABLES
Table 1 Global Cancer Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Cancer Vaccines Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Cancer Vaccines Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Cancer Vaccines Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Cancer Vaccines Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Cancer Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 9 Global Cancer Vaccines Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 11 Global Cancer Vaccines Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 13 Global Cancer Vaccines Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 14 Global Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 15 Global Cancer Vaccines Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 16 Global Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 17 Global Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 18 Global Cancer Vaccines Market Value, By Region, 2022-2033 (US$ Billion)
Table 19 North America Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 20 North America Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 21 North America Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 22 North America Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 23 North America Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 24 North America Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Europe Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 26 Europe Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 27 Europe Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 28 Europe Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Europe Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Europe Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 36 Asia-Pacific Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 37 South America Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 38 South America Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 39 South America Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 40 South America Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 41 South America Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 42 South America Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 43 Middle East and Africa Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 44 Middle East and Africa Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 45 Middle East and Africa Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 46 Middle East and Africa Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 47 Middle East and Africa Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 48 Middle East and Africa Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 49 Merck & Co., Inc.: Overview
Table 50 Merck & Co., Inc.: Product Portfolio
Table 51 Merck & Co., Inc.: Key Developments
Table 52 GlaxoSmithKline plc (GSK): Overview
Table 53 GlaxoSmithKline plc (GSK): Product Portfolio
Table 54 GlaxoSmithKline plc (GSK): Key Developments
Table 55 Dendreon Pharmaceuticals LLC: Overview
Table 56 Dendreon Pharmaceuticals LLC: Product Portfolio
Table 57 Dendreon Pharmaceuticals LLC: Key Developments
Table 1 Global Cancer Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Cancer Vaccines Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Cancer Vaccines Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Cancer Vaccines Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Cancer Vaccines Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Cancer Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 9 Global Cancer Vaccines Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 11 Global Cancer Vaccines Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 13 Global Cancer Vaccines Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 14 Global Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 15 Global Cancer Vaccines Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 16 Global Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 17 Global Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 18 Global Cancer Vaccines Market Value, By Region, 2022-2033 (US$ Billion)
Table 19 North America Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 20 North America Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 21 North America Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 22 North America Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 23 North America Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 24 North America Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Europe Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 26 Europe Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 27 Europe Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 28 Europe Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Europe Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Europe Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 36 Asia-Pacific Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 37 South America Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 38 South America Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 39 South America Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 40 South America Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 41 South America Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 42 South America Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 43 Middle East and Africa Cancer Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 44 Middle East and Africa Cancer Vaccines Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 45 Middle East and Africa Cancer Vaccines Market Value, By Technology, 2022-2033 (US$ Billion)
Table 46 Middle East and Africa Cancer Vaccines Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 47 Middle East and Africa Cancer Vaccines Market Value, By End User, 2022-2033 (US$ Billion)
Table 48 Middle East and Africa Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 49 Merck & Co., Inc.: Overview
Table 50 Merck & Co., Inc.: Product Portfolio
Table 51 Merck & Co., Inc.: Key Developments
Table 52 GlaxoSmithKline plc (GSK): Overview
Table 53 GlaxoSmithKline plc (GSK): Product Portfolio
Table 54 GlaxoSmithKline plc (GSK): Key Developments
Table 55 Dendreon Pharmaceuticals LLC: Overview
Table 56 Dendreon Pharmaceuticals LLC: Product Portfolio
Table 57 Dendreon Pharmaceuticals LLC: Key Developments
LIST OF FIGURES
Figure 1 Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 5 Global Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 6 Global Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 7 Global Cancer Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 8 Global Cancer Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 9: Preventive Cancer Vaccines Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 10 Therapeutic Cancer Vaccines Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Cancer Vaccines Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 12 Prostate Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 13: Cervical Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 14 Lung Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 15: Bladder Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 16: Other Cancer Types in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Cancer Vaccines Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 18 Protein-based Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 19 Nucleic acid-based (DNA, RNA/mRNA) Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 20 Whole-cell Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 21 Viral vector Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 22 Dendritic cell Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 23 Recombinant/adjuvant Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Cancer Vaccines Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 25 Intramuscular Route of Administration in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 26 Intravenous Route of Administration in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 27: Other Route of Administration in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 28 Global Cancer Vaccines Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 29 Hospitals End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 30 Clinics End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 31 Cancer Treatment Centers End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 32 Government Entities End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 33 Other End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 34 Global Cancer Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 35 North America Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 36 North America Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 37 North America Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 38 North America Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 39 North America Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 40 North America Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 41 North America Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 42 Europe Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 43 Europe Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 44 Europe Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 45 Europe Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 46 Europe Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 47 Europe Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 48 Europe Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 49 Asia-Pacific Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 50 Asia-Pacific Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 51 Asia-Pacific Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 52 Asia-Pacific Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 53 Asia-Pacific Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 54 Asia-Pacific Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 55 Asia-Pacific Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 56 South America Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 57 South America Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 58 South America Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 59 South America Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 60 South America Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 61 South America Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 62 South America Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 63 Middle East and Africa Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 64 Middle East and Africa Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 65 Middle East and Africa Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 66 Middle East and Africa Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 67 Middle East and Africa Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 68 Middle East and Africa Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 69 Merck & Co., Inc.: Financials
Figure 70 GlaxoSmithKline plc (GSK): Financials
Figure 71 Dendreon Pharmaceuticals LLC: Financials
Figure 1 Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 5 Global Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 6 Global Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 7 Global Cancer Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 8 Global Cancer Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 9: Preventive Cancer Vaccines Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 10 Therapeutic Cancer Vaccines Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Cancer Vaccines Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 12 Prostate Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 13: Cervical Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 14 Lung Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 15: Bladder Cancer Cancer Type in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 16: Other Cancer Types in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Cancer Vaccines Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 18 Protein-based Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 19 Nucleic acid-based (DNA, RNA/mRNA) Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 20 Whole-cell Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 21 Viral vector Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 22 Dendritic cell Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 23 Recombinant/adjuvant Technology in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Cancer Vaccines Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 25 Intramuscular Route of Administration in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 26 Intravenous Route of Administration in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 27: Other Route of Administration in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 28 Global Cancer Vaccines Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 29 Hospitals End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 30 Clinics End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 31 Cancer Treatment Centers End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 32 Government Entities End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 33 Other End User in Global Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 34 Global Cancer Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 35 North America Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 36 North America Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 37 North America Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 38 North America Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 39 North America Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 40 North America Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 41 North America Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 42 Europe Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 43 Europe Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 44 Europe Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 45 Europe Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 46 Europe Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 47 Europe Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 48 Europe Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 49 Asia-Pacific Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 50 Asia-Pacific Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 51 Asia-Pacific Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 52 Asia-Pacific Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 53 Asia-Pacific Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 54 Asia-Pacific Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 55 Asia-Pacific Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 56 South America Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 57 South America Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 58 South America Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 59 South America Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 60 South America Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 61 South America Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 62 South America Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 63 Middle East and Africa Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 64 Middle East and Africa Cancer Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 65 Middle East and Africa Cancer Vaccines Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 66 Middle East and Africa Cancer Vaccines Market Share, By Technology, 2024 & 2033 (%)
Figure 67 Middle East and Africa Cancer Vaccines Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 68 Middle East and Africa Cancer Vaccines Market Share, By End User, 2024 & 2033 (%)
Figure 69 Merck & Co., Inc.: Financials
Figure 70 GlaxoSmithKline plc (GSK): Financials
Figure 71 Dendreon Pharmaceuticals LLC: Financials
